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Tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor,
which augments cyclic guanine monophosphate in the
central nervous system, has been shown to increase neu-
rogenesis, angiogenesis, and synaptogenesis, and to
improve functional outcomes compared with placebo in a
rat model of ischemic stroke [1].
Sildenafil, another PDE5 inhibitor, also showed similar
effects in preclinical studies of stroke models in the rat [1].
Although infrequently, sildenafil has been also associated
with serious cardiovascular events such as ischemic stroke,
intracerebral hemorrhage, and anterior ischemic optic
neuropathy [2–6]. There is only one study reporting an
association between tadalafil usage and stroke [7]. Here,
we describe a patient who sustained a subcortical infarction
after tadalafil use.
A 52-year-old man was admitted to our institution
because of right facial weakness, slurred speech, and right
hemiparesis developed about 2 h after taking 10 mg of
tadalafil without participating in sexual intercourse. Four
months before the beginning of the present complaints,
after he had ingested the first and only other dose of 10 mg
of tadalafil, he experienced the same neurologic symptoms,
again without achieving an erection or participating in
sexual intercourse. In that occasion, however, his symp-
toms slowly returned to baseline over 1 h.
On admission to our hospital, the neurologic examina-
tion showed that the patient was mildly dysarthric, had
right lower facial weakness, 3/5 strength (Medical
Research Council Scale) in his right upper extremity, and
4/5 strength in his right lower extremity. Sensory exami-
nation and coordination tests were normal. His medical
history was normal, and he was taking no medications. He
was a non-smoker and did not drink alcohol. His blood
pressure and the cardiovascular examination were normal.
Brain MRI performed the day after admission demon-
strated an acute/subacute infarction of the posterior limb of
the left internal capsule (Fig. 1). On magnetic resonance
angiography there were no significant stenoses of extra-
cranial or intracranial vessels. Cardiac evaluation including
heart ultrasound was normal. Immunologic tests and
screening for thrombophilias were also normal. A therapy
with 300 mg of aspirin per day was started for 1 week, and
was then reduced to 150 mg per day.
After 1- and 2-year follow-up, the patient showed good
recovery. He did not take tadalafil or others PDE5 inhibi-
tors and did not suffer more stroke episodes.
Oral PDE5 inhibitors (sildenafil, vardenafil, tadalafil)
are the recommended first-line therapy for erectile dys-
function [8]. All three PDE5 inhibitors share a common
mechanism of action, preventing cyclic guanosine mono-
phosphate (cGMP) breakdown. Sildenafil and vardenafil
have similar molecular structures, but tadalafil is structur-
ally different, which is reflected in its pharmacokinetic
profile and its selectivity for PDE isozymes [8]. All three
PDE5 inhibitors are rapidly absorbed from the gastroin-
testinal tract and peak plasma concentrations of tadalafil
are reached after approximately 2 h. Sildenafil and
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vardenafil both have a terminal half-life of approximately
4 h, and tadalafil has a half-life of 17.5 h [8].
Class-specific side effects include headache, flushing,
nasal congestion, dyspepsia and myalgia [8]. PDE5 inhib-
itors use is not recommended in men who have recent
history of stroke or myocardial infarction (within the last
6–8 weeks), or who have significantly low blood pressure,
uncontrolled high blood pressure, unstable angina, severe
cardiac failure, severe liver impairment or end-stage kid-
ney disease requiring dialysis. Moreover, both sildenafil
and tadalafil have been associated with an increased risk of
non-arteritic anterior ischemic optic neuropathy [6],
but sildenafil has been also recently linked to transient
ischemic attack, ischemic stroke and intracerebral hemor-
rhage [2–5].
This report, describing a patient that developed an
ischemic stroke 2 h after ingesting 10 mg of tadalafil,
emphasizes that ischemic cerebrovascular events, although
rarely, may develop after exposure to multiple PDE5
inhibitors, not only sildenafil [7].
Many findings from our report strongly support a causal
relationship between the symptoms of the patient and
tadalafil: (1) the time range between the assumption of
tadalafil and the occurrence of ischemic stroke is consistent
with the pharmacokinetic of the drug; (2) the patient
experienced the same symptomatology in both the occa-
sions of tadalafil ingestion; (3) in the two following years
of follow-up the patient abstained from PDE5 inhibitors
use, and had no clinical cerebrovascular events. However,
the lack of transesophageal echocardiography and pro-
longed cardiac monitoring, prevent the definitive exclusion
of an independent cardioembolic source. The mechanism
by which tadalafil induced symptomatic cerebrovascular
disease in our patient remains not fully understood. As in a
previous report, a transient lowering of blood pressure is
the most suggestive cause of our patient’s symptoms,
although a cardioembolic source, provoked by a transient
brief atrial fibrillation is also plausible [2, 4].
In conclusion, our case suggests that cerebrovascular
ischemic events, even if uncommon adverse effects, should
be taken into consideration by the physicians prescribing
this drug, especially in the presence of other stroke risk
factors. Future studies should deeply investigate this seri-
ous and potentially life-threatening association.
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Fig. 1 Brain MRI showing small round lesion, hyperintense in T2-
weighted sequences, located in the posterior limb of the left internal
capsule and extending to the caudate nucleus, consistent with an
acute/subacute infarct
Neurol Sci
123
Author's personal copy
